XCR1 and depressive symptom measurement: The BAs suppress the synthesis of BDNF to aggravate anxiety and depression when targeting farnesoid X receptor, but they alleviate anxiety and depression by inhibiting neuroinflammation, oxidative stress, and nitrosation stress when targeting Takeda G-protein-coupled receptor 5 [87, 195].